Most multivitamins sold in the United States do not contain vitamin K. When a product does include it, the amount is usually modest—commonly 60–120 micrograms (mcg) per daily serving—and the form matters as much as the number on the label. Standard adult formulas also tend to omit vitamin K on purpose, because it interacts with warfarin and other vitamin K antagonist anticoagulants.

That single answer hides a formulation story worth understanding. Vitamin K is not one molecule but a family of fat-soluble compounds with different absorption behavior, different half-lives, and different regulatory ceilings. Whether a multivitamin carries it depends on who the product is designed to serve, what form the manufacturer can source at a stable cost, and how the label handles a nutrient that has both a daily value and a documented drug interaction.

Two Forms, Two Absorption Pathways

Vitamin K exists in two dietary forms. Phylloquinone (vitamin K1) comes from leafy greens and is the form most multivitamins use when they include K at all. Menaquinones (vitamin K2), especially MK-4 and MK-7, come from fermented foods and gut bacteria and appear in some specialty supplements. The difference is not cosmetic.

Phylloquinone is absorbed in the small intestine through the same bile-dependent pathway as dietary fat. It hitches onto chylomicrons, gets routed through the liver, and is largely cleared within a day or two. MK-7, by contrast, travels on LDL and has a substantially longer circulation time—measured in days rather than hours—which is why some formulators prefer it for sustained exposure. This is a pharmacokinetic argument, not proof of superior clinical outcomes.

The mechanism that matters for safety is the vitamin K cycle. Vitamin K hydroquinone is oxidized to vitamin K epoxide while it activates glutamate residues on clotting factors II, VII, IX, and X. The enzyme vitamin K epoxide reductase (VKORC1) then recycles the epoxide back to the active form. Warfarin blocks VKORC1. Any exogenous vitamin K—dietary or supplemental—competes with that blockade by supplying substrate the drug is trying to deplete. This is why a multivitamin containing K1 or MK-7 can blunt anticoagulation, and why the effect is dose- and timing-dependent rather than binary.

The practical upshot: vitamin K status is a cycle, not a tank. Small daily inputs matter more than a single large dose, and consistency matters more than total weekly intake.

Quantified Context: What Labels Actually Say

In the United States, vitamin K has a Daily Value of 120 mcg for adults and children age 4 and older, set by the FDA for labeling purposes. That is a reference number for nutrition labels, not a clinical target. Typical dietary intake in American adults runs roughly in the same range, driven almost entirely by green vegetables and oils.

Multivitamin products cluster into recognizable patterns. The table below compares common categories, using ranges that reflect mainstream US product formulations rather than any single brand.

Product category Vitamin K included? Typical amount per serving Form used Primary rationale
Standard adult multivitamin Usually no 0 mcg — Avoids warfarin interaction; K is easy to get from diet
Adult formula with K Often yes 60–120 mcg Phylloquinone (K1) Rounds out label toward DV
Prenatal multivitamin Usually no 0 mcg — K not a recognized prenatal gap nutrient in most products
Bone or heart "K2" supplement Yes Variable, often 45–180 mcg MK-7 Menaquinone-7 Longer half-life marketing and mechanistic rationale
Senior or "complete" formula Sometimes 20–80 mcg K1 or MK-7 Differentiation; inconsistent across brands
Bariatric or specialized formula Sometimes Variable Usually K1 Mirrors specific clinical nutrition requirements

The pattern is deliberate. A manufacturer that leaves K out avoids a liability question and loses nothing on a label that already meets DV targets for vitamins A, C, D, and E. A manufacturer that adds K gains a marketing line—"supports bone and cardiovascular health"—at a modest ingredient cost. The amounts added are typically calibrated to be meaningful on a label without approaching the tolerable upper intake level, which the Institute of Medicine declined to establish for vitamin K because toxicity from oral intake has not been documented in healthy adults.

That absence of a UL is not a license to ignore the nutrient. It reflects the fact that natural vitamin K has low bioavailability and rapid clearance, not that high doses are proven safe in every population.

Edge Cases Where the Answer Changes

Three groups make the "does it have K" question consequential rather than academic.

People taking warfarin face the sharpest edge. Clinical guidance from anticoagulation clinics consistently emphasizes stable, consistent vitamin K intake rather than avoidance. A multivitamin that suddenly introduces 90 mcg of K1 into a previously K-free regimen can lower the INR within days. The reverse—stopping a K-containing multivitamin—can push INR upward. The hazard is the change, not the presence.

People with fat malabsorption—cholestatic liver disease, cystic fibrosis, short bowel syndrome, or prior bariatric surgery—may depend on supplemental K because dietary absorption is impaired. For them, a K-free multivitamin is a gap, and clinicians often address it with a dedicated product rather than a combination pill.

Newborns are a separate regulatory universe. The American Academy of Pediatrics recommends a single intramuscular dose of vitamin K1 at birth to prevent vitamin K deficiency bleeding, and this is not a multivitamin question at all. Oral K supplements are not a substitute for that prophylaxis.

One counterintuitive detail deserves emphasis: a multivitamin labeled "complete" can still be nutritionally incomplete for K. The word carries no regulatory definition, and the FDA does not require a product to contain every vitamin to use it.

Misconceptions That Persist on Shelves

Several beliefs about vitamin K in multivitamins survive because they sound mechanistic and are hard to falsify at the point of sale.

The first is that K2 is categorically superior to K1. The mechanistic case for MK-7—longer half-life, extrahepatic distribution—is real, and some trials report effects on arterial stiffness markers. But the evidence base for hard clinical outcomes remains thin compared with the decades of data on K1 and coagulation. A multivitamin with K2 is not automatically better; it is differently formulated.

The second is that a K-containing multivitamin "thins" or "thickens" blood on its own. It does neither. Vitamin K does not anticoagulate; it supports the synthesis of functional clotting factors. The interaction with warfarin is competitive antagonism, not a direct effect.

The third is that vitamin K is toxic at high doses. Oral phylloquinone has not produced documented toxicity in healthy adults, which is why no UL exists. That is a statement about observed harm, not a guarantee of unlimited safety, and it does not extend to the injectable forms used clinically.

The fourth is that label amount equals absorbed amount. Fat-soluble vitamins taken without dietary fat are absorbed less efficiently. A multivitamin taken with a fat-containing meal delivers more K than the same pill taken with black coffee.

Red flags worth heeding:

Any K-containing product started or stopped abruptly while on warfarin, without informing the anticoagulation team. "Complete" or "all-in-one" claims on a label whose supplement facts panel shows 0 mcg vitamin K. Prenatal products marketed as covering every nutrient, when K is absent and not clinically indicated as a prenatal supplement. High-dose MK-7 products sold with cardiovascular claims that exceed what the trial literature supports. Bariatric patients assumed to be covered by a general adult multivitamin when their absorption profile differs. Any product recommending doses far above the 120 mcg DV without a stated clinical rationale.

Practical Actions for Reading a Label

The steps below convert the science into decisions a reader can make in a store aisle or a pharmacy counter.

Turn the bottle over and read the Supplement Facts panel, not the front label. Vitamin K appears as "vitamin K" or "phytonadione" in mcg. If the row is absent or reads 0 mcg, the product contains none. If you take warfarin or another vitamin K antagonist, treat any new multivitamin as a regimen change. Tell your anticoagulation clinician before starting and check INR on the schedule they specify—typically within a week of the change. If you have fat malabsorption or have had bariatric surgery, ask whether a dedicated vitamin K product is appropriate rather than assuming a multivitamin covers it. Take a K-containing multivitamin with a meal that contains fat. Absorption of fat-soluble vitamins depends on it, and the label amount assumes normal absorption. Compare the mcg on the label with the 120 mcg DV to judge whether the product is a token amount or a meaningful contribution. Amounts under about 20 mcg are unlikely to move the needle much either way. Do not stop a K-containing multivitamin abruptly if you are anticoagulated. Consistency is the clinical goal; the transition itself carries risk.

For most healthy adults not on anticoagulation, the practical answer is that the multivitamin is a minor player. Dietary sources—cooked kale, spinach, broccoli, soybean and canola oils—deliver vitamin K reliably, and a K-free multivitamin leaves no meaningful gap.

Limits of What the Evidence Supports

The honest boundary of this topic is that formulation data and coagulation mechanics are well established, while outcome data for K2 in multivitamins are not. The FDA sets Daily Values for labeling but does not certify that a multivitamin delivers clinical benefit from its K content. The Institute of Medicine's decision not to set a UL reflects absence of observed oral toxicity, not a demonstrated therapeutic window. And no authoritative body recommends a specific mcg target for vitamin K in a multivitamin, because the nutrient's requirement is defined by coagulation status and dietary pattern rather than by a universal supplement dose.

What can be concluded with confidence is narrower and more useful: most US multivitamins omit vitamin K, those that include it usually carry 60–120 mcg of phylloquinone, K2 products exist with a different pharmacokinetic profile and a weaker outcome evidence base, and the population for whom this matters most is the one taking warfarin. Everyone else is reading a label for a nutrient their dinner already supplies.